title: Ophthalmic statistics note 2: absence of evidence is not evidence of absence.
authors.affiliation: NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, , London, UK.
authors.forename: Catey
authors.initials: C
authors.lastname: Bunce
authors.forename: Krishna V
authors.initials: KV
authors.lastname: Patel
authors.forename: Wen
authors.initials: W
authors.lastname: Xing
authors.forename: Nick
authors.initials: N
authors.lastname: Freemantle
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Doré
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D019317:Evidence-Based Medicine / Q000193:education; D006112:Gravitation; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000534:rehabilitation / Q000601:surgery; D009885:Ophthalmology / Q000193:education*; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D011187:Posture; D000069579:Ranibizumab; D012086:Reoperation / Q000706:statistics & numerical data; D012167:Retinal Perforations / Q000188:drug therapy / Q000534:rehabilitation / Q000601:surgery*; D018570:Risk Assessment; D012307:Risk Factors; D014821:Vitrectomy / Q000009:adverse effects* / Q000534:rehabilitation
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Epidemiology